InMed Pharma Files Routine 8-K, Confirms Address & Contact Info
Ticker: INM · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, regulatory-filing
TL;DR
**InMed Pharma filed a boilerplate 8-K with no new material news.**
AI Summary
This 8-K filing from InMed Pharmaceuticals Inc. on January 16, 2024, is a routine administrative update, primarily confirming its current address as Suite 310 - 815 W. Hastings Street, Vancouver, B.C., Canada V6C 1B4, and its telephone number as (604) 669-7207. It also reiterates its incorporation in British Columbia and its Commission File Number 001-39685. This filing is purely informational and does not contain any new financial or operational news, meaning it has no direct impact on the stock's value or an investor's decision.
Why It Matters
This filing is purely administrative, confirming basic company information like address and phone number. It contains no new material information that would impact an investor's decision or the stock price.
Risk Assessment
Risk Level: low — This 8-K is a standard administrative filing and does not introduce any new financial, operational, or legal risks to the company or its investors.
Analyst Insight
A smart investor would recognize this 8-K as a non-event, containing only administrative updates, and would not make any trading decisions based solely on this filing. Focus should remain on material news, financial performance, and pipeline developments.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — the filer of the 8-K
- British Columbia (company) — state of incorporation for InMed Pharmaceuticals Inc.
- 001-39685 (dollar_amount) — Commission File Number
- January 16, 2024 (dollar_amount) — Date of earliest event reported
- Suite 310 - 815 W. Hastings Street, Vancouver, B.C., Canada V6C 1B4 (company) — Address of Principal Executive Offices
- (604) 669-7207 (dollar_amount) — Company's telephone number
FAQ
What is the primary purpose of this 8-K filing by InMed Pharmaceuticals Inc.?
The primary purpose of this 8-K filing, dated January 16, 2024, is to provide a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, essentially confirming administrative details such as the company's address and contact information.
What is InMed Pharmaceuticals Inc.'s current business address as stated in the filing?
According to the filing, InMed Pharmaceuticals Inc.'s current business address is Suite 310 - 815 W. Hastings Street, Vancouver, B.C., Canada V6C 1B4.
What is the company's telephone number listed in this 8-K?
The company's telephone number, including area code, listed in this 8-K is (604) 669-7207.
In which jurisdiction is InMed Pharmaceuticals Inc. incorporated?
InMed Pharmaceuticals Inc. is incorporated in British Columbia, as stated under 'State or Other Jurisdiction of Incorporation' in the filing.
Does this 8-K filing contain any information about new financial results, mergers, or significant operational changes?
No, this 8-K filing does not contain any information about new financial results, mergers, acquisitions, or significant operational changes. It is a routine administrative update of company contact and incorporation details.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-16 14:12:30
Filing Documents
- ea191665-8k_inmedpharma.htm (8-K) — 28KB
- ea191665ex99-1_inmedpharma.htm (EX-99.1) — 26KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-003661.txt ( ) — 279KB
- inm-20240116.xsd (EX-101.SCH) — 3KB
- inm-20240116_def.xml (EX-101.DEF) — 26KB
- inm-20240116_lab.xml (EX-101.LAB) — 35KB
- inm-20240116_pre.xml (EX-101.PRE) — 24KB
- ea191665-8k_inmedpharma_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 16, 2024, the Company outlined key accomplishments from 2023 and provides key strategic priorities for 2024. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated January 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: January 16, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2